Johansson I - Search Results

1

Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype.

Wennerholm A, Johansson I, Massele AY, Lande M, Alm C, Aden-Abdi Y, Dahl ML, Ingelman-Sundberg M, Bertilsson L, Gustafsson LL. Wennerholm A, et al. Among authors: johansson i. Pharmacogenetics. 1999 Dec;9(6):707-14. Pharmacogenetics. 1999. PMID: 10634133

2

Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects.

Dahl ML, Yue QY, Roh HK, Johansson I, Säwe J, Sjöqvist F, Bertilsson L. Dahl ML, et al. Among authors: johansson i. Pharmacogenetics. 1995 Jun;5(3):159-64. doi: 10.1097/00008571-199506000-00004. Pharmacogenetics. 1995. PMID: 7550367

3

Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.

Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Dahl ML, et al. Among authors: johansson i. J Pharmacol Exp Ther. 1995 Jul;274(1):516-20. J Pharmacol Exp Ther. 1995. PMID: 7616439

4

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.

Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Johansson I, et al. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11825-9. doi: 10.1073/pnas.90.24.11825. Proc Natl Acad Sci U S A. 1993. PMID: 7903454 Free PMC article.

5

Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.

Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Johansson I, et al. Mol Pharmacol. 1994 Sep;46(3):452-9. Mol Pharmacol. 1994. PMID: 7935325

6

Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.

Bertilsson L, Meese CO, Yue QY, Dahl ML, Ingelman-Sundberg M, Johansson I, Säwe J, Eichelbaum M. Bertilsson L, et al. Among authors: johansson i. Pharmacogenetics. 1993 Apr;3(2):94-100. doi: 10.1097/00008571-199304000-00005. Pharmacogenetics. 1993. PMID: 8100167

7

PCR-based genotyping for duplicated and deleted CYP2D6 genes.

Johansson I, Lundqvist E, Dahl ML, Ingelman-Sundberg M. Johansson I, et al. Pharmacogenetics. 1996 Aug;6(4):351-5. doi: 10.1097/00008571-199608000-00008. Pharmacogenetics. 1996. PMID: 8873221

8

Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.

Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, Bertilsson L. Roh HK, et al. Among authors: johansson i. Pharmacogenetics. 1996 Oct;6(5):441-7. doi: 10.1097/00008571-199610000-00008. Pharmacogenetics. 1996. PMID: 8946476

9

Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.

Herrlin K, Massele AY, Jande M, Alm C, Tybring G, Abdi YA, Wennerholm A, Johansson I, Dahl ML, Bertilsson L, Gustafsson LL. Herrlin K, et al. Among authors: johansson i. Clin Pharmacol Ther. 1998 Oct;64(4):391-401. doi: 10.1016/S0009-9236(98)90070-4. Clin Pharmacol Ther. 1998. PMID: 9797796

10

Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine.

Bernal ML, Sinues B, Johansson I, McLellan RA, Wennerholm A, Dahl ML, Ingelman-Sundberg M, Bertilsson L. Bernal ML, et al. Among authors: johansson i. Pharmacogenetics. 1999 Oct;9(5):657-60. Pharmacogenetics. 1999. PMID: 10591547 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

806 results

Search Page

Filters